Life sciences industry weighs how to address opioid crisis
BOSTON (AP) — Massachusetts life sciences executives are considering what their industry should be doing to address the nation’s opioid abuse epidemic.
That topic will be the focus of a panel discussion Wednesday morning at the Massachusetts Biotechnology Council’s annual Policy Leadership Breakfast.
Some 300 life sciences executives and state lawmakers are expected to attend the event at the Omni Parker House in Boston.
Among the panelists are Massachusetts Medical Society President Dennis Dimitri, Massachusetts Health and Human Services Secretary Marylou Sudders and Michael Heffernan, founder of Collegium Pharmaceutical, in Canton, Massachusetts, which is developing “abuse-deterrent” painkillers.
State Attorney General Maura Healey is scheduled to give the opening remarks at the event.
The Massachusetts Biotechnology Council is a non-profit trade association founded in 1985.